 Seena Aisner
Concepts (269)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Lobular | 1 | 2022 | 55 | 0.680 |
Why?
| | Soft Tissue Neoplasms | 5 | 2009 | 128 | 0.570 |
Why?
| | Bone Neoplasms | 4 | 2008 | 255 | 0.460 |
Why?
| | Thymus Neoplasms | 3 | 2011 | 30 | 0.450 |
Why?
| | Diagnosis, Differential | 10 | 2022 | 1501 | 0.430 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 7 | 2017 | 1186 | 0.430 |
Why?
| | Lung Neoplasms | 10 | 2017 | 2660 | 0.380 |
Why?
| | Octreotide | 2 | 2010 | 23 | 0.370 |
Why?
| | Sarcoma, Alveolar Soft Part | 2 | 2010 | 6 | 0.360 |
Why?
| | Liposarcoma | 3 | 2009 | 31 | 0.350 |
Why?
| | Prednisone | 2 | 2010 | 221 | 0.340 |
Why?
| | Breast Neoplasms | 3 | 2022 | 2365 | 0.340 |
Why?
| | Lipoma | 2 | 2009 | 17 | 0.330 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2010 | 192 | 0.330 |
Why?
| | Translocation, Genetic | 3 | 2010 | 118 | 0.330 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2010 | 52 | 0.310 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2010 | 72 | 0.310 |
Why?
| | Chondroblastoma | 2 | 2006 | 3 | 0.290 |
Why?
| | Biopsy, Fine-Needle | 4 | 2014 | 68 | 0.290 |
Why?
| | ErbB Receptors | 3 | 2016 | 632 | 0.280 |
Why?
| | Fibula | 1 | 2008 | 36 | 0.270 |
Why?
| | Nevus, Spindle Cell | 1 | 2007 | 1 | 0.270 |
Why?
| | Angiofibroma | 1 | 2007 | 6 | 0.270 |
Why?
| | Leiomyoma | 1 | 2008 | 59 | 0.260 |
Why?
| | Biomarkers, Tumor | 5 | 2017 | 1319 | 0.260 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2006 | 7 | 0.250 |
Why?
| | Tibia | 1 | 2008 | 175 | 0.240 |
Why?
| | Femoral Neoplasms | 1 | 2006 | 10 | 0.240 |
Why?
| | Head and Neck Neoplasms | 2 | 2012 | 562 | 0.230 |
Why?
| | Forkhead Transcription Factors | 1 | 2006 | 203 | 0.230 |
Why?
| | Image Enhancement | 1 | 2006 | 199 | 0.220 |
Why?
| | Cheek | 1 | 2004 | 16 | 0.220 |
Why?
| | Facial Neoplasms | 1 | 2004 | 19 | 0.220 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2017 | 1145 | 0.210 |
Why?
| | Immunohistochemistry | 10 | 2014 | 1705 | 0.210 |
Why?
| | Small Cell Lung Carcinoma | 2 | 2016 | 121 | 0.200 |
Why?
| | Microtomy | 1 | 2003 | 4 | 0.190 |
Why?
| | Cytological Techniques | 1 | 2003 | 28 | 0.190 |
Why?
| | Pain | 2 | 2008 | 785 | 0.190 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2017 | 1961 | 0.190 |
Why?
| | Biopsy, Needle | 1 | 2003 | 184 | 0.180 |
Why?
| | Vulvar Neoplasms | 1 | 2022 | 13 | 0.180 |
Why?
| | Subcutaneous Tissue | 1 | 2022 | 26 | 0.180 |
Why?
| | Paclitaxel | 2 | 2014 | 256 | 0.170 |
Why?
| | Breast | 1 | 2022 | 157 | 0.170 |
Why?
| | Hypothalamus | 1 | 2022 | 160 | 0.170 |
Why?
| | Middle Aged | 25 | 2019 | 35968 | 0.160 |
Why?
| | Magnetic Resonance Imaging | 3 | 2008 | 3887 | 0.160 |
Why?
| | Chromosomes, Human, Pair 11 | 2 | 2010 | 59 | 0.150 |
Why?
| | In Situ Hybridization, Fluorescence | 4 | 2010 | 323 | 0.150 |
Why?
| | Vulva | 2 | 2022 | 24 | 0.150 |
Why?
| | Skin Neoplasms | 1 | 2006 | 850 | 0.140 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 161 | 0.140 |
Why?
| | Humans | 38 | 2022 | 144665 | 0.140 |
Why?
| | Thymoma | 2 | 2011 | 37 | 0.130 |
Why?
| | Selenium | 2 | 2017 | 49 | 0.130 |
Why?
| | Aged | 19 | 2019 | 25955 | 0.130 |
Why?
| | Bevacizumab | 1 | 2017 | 168 | 0.130 |
Why?
| | Urinary Bladder | 1 | 2019 | 192 | 0.130 |
Why?
| | Female | 27 | 2022 | 78301 | 0.120 |
Why?
| | Male | 26 | 2017 | 72425 | 0.120 |
Why?
| | Erlotinib Hydrochloride | 1 | 2016 | 72 | 0.120 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2016 | 37 | 0.120 |
Why?
| | Anilides | 1 | 2016 | 84 | 0.120 |
Why?
| | Disease-Free Survival | 4 | 2013 | 768 | 0.120 |
Why?
| | Carcinoma | 2 | 2011 | 224 | 0.120 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2019 | 260 | 0.120 |
Why?
| | Neoplasm Staging | 4 | 2017 | 1465 | 0.120 |
Why?
| | Adult | 18 | 2017 | 40486 | 0.110 |
Why?
| | Sputum | 1 | 2017 | 308 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2013 | 1437 | 0.110 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 201 | 0.110 |
Why?
| | Isotretinoin | 1 | 2014 | 26 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2014 | 238 | 0.100 |
Why?
| | DNA Methylation | 2 | 2017 | 664 | 0.100 |
Why?
| | Angiomatosis | 1 | 2013 | 5 | 0.100 |
Why?
| | Breast Diseases | 1 | 2013 | 23 | 0.100 |
Why?
| | Vulvar Diseases | 1 | 2013 | 9 | 0.100 |
Why?
| | Polyps | 1 | 2013 | 14 | 0.100 |
Why?
| | Adenoma, Oxyphilic | 1 | 2013 | 7 | 0.100 |
Why?
| | Receptors, Prostaglandin E, EP3 Subtype | 1 | 2013 | 3 | 0.100 |
Why?
| | Genes, ras | 1 | 2013 | 96 | 0.100 |
Why?
| | Receptors, Prostaglandin E, EP4 Subtype | 1 | 2013 | 8 | 0.100 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2013 | 37 | 0.100 |
Why?
| | Interferon-alpha | 1 | 2014 | 194 | 0.100 |
Why?
| | Hyperplasia | 1 | 2013 | 177 | 0.100 |
Why?
| | Immunoenzyme Techniques | 3 | 2016 | 197 | 0.090 |
Why?
| | Pyridines | 1 | 2016 | 603 | 0.090 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2010 | 26 | 0.090 |
Why?
| | Smad Proteins | 1 | 2012 | 43 | 0.090 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2009 | 72 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 2 | 2009 | 67 | 0.090 |
Why?
| | Genetic Association Studies | 1 | 2013 | 369 | 0.090 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2011 | 20 | 0.080 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2016 | 643 | 0.080 |
Why?
| | Autophagy | 1 | 2013 | 284 | 0.080 |
Why?
| | Carboplatin | 1 | 2011 | 161 | 0.080 |
Why?
| | Pneumonectomy | 3 | 2017 | 167 | 0.080 |
Why?
| | Protein Kinase Inhibitors | 1 | 2016 | 971 | 0.080 |
Why?
| | World Health Organization | 1 | 2010 | 104 | 0.080 |
Why?
| | Chromosomes, Human, X | 1 | 2010 | 76 | 0.080 |
Why?
| | Lipid Metabolism | 1 | 2013 | 524 | 0.080 |
Why?
| | Tidal Volume | 1 | 2010 | 111 | 0.070 |
Why?
| | Survival Analysis | 4 | 2017 | 1370 | 0.070 |
Why?
| | Fibroma | 1 | 2009 | 20 | 0.070 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2010 | 58 | 0.070 |
Why?
| | Genes, p16 | 1 | 2009 | 13 | 0.070 |
Why?
| | Dietary Supplements | 1 | 2013 | 575 | 0.070 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 475 | 0.070 |
Why?
| | Positive-Pressure Respiration | 1 | 2010 | 112 | 0.070 |
Why?
| | Cell Dedifferentiation | 1 | 2009 | 32 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 3 | 2008 | 2753 | 0.070 |
Why?
| | Reproducibility of Results | 4 | 2016 | 3414 | 0.070 |
Why?
| | Aged, 80 and over | 6 | 2013 | 8283 | 0.070 |
Why?
| | Carcinoma, Renal Cell | 1 | 2010 | 234 | 0.070 |
Why?
| | Tissue Fixation | 2 | 2008 | 36 | 0.070 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 2006 | 15 | 0.060 |
Why?
| | Collagen | 1 | 2009 | 450 | 0.060 |
Why?
| | Cytodiagnosis | 1 | 2006 | 31 | 0.060 |
Why?
| | Forkhead Box Protein O1 | 1 | 2006 | 35 | 0.060 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2008 | 211 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2009 | 532 | 0.060 |
Why?
| | DNA, Neoplasm | 1 | 2006 | 158 | 0.060 |
Why?
| | Kidney Neoplasms | 1 | 2010 | 412 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2137 | 0.060 |
Why?
| | Adenoma | 1 | 2008 | 218 | 0.060 |
Why?
| | Gene Rearrangement | 1 | 2006 | 155 | 0.060 |
Why?
| | Prostatic Neoplasms | 1 | 2013 | 978 | 0.060 |
Why?
| | Pain Measurement | 1 | 2008 | 554 | 0.060 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2008 | 454 | 0.060 |
Why?
| | Rare Diseases | 1 | 2006 | 115 | 0.060 |
Why?
| | Coccidioides | 1 | 2004 | 6 | 0.050 |
Why?
| | Coccidioidomycosis | 1 | 2004 | 7 | 0.050 |
Why?
| | Shoulder Pain | 1 | 2004 | 36 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2350 | 0.050 |
Why?
| | Salivary Gland Neoplasms | 1 | 2004 | 39 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2019 | 2019 | 0.050 |
Why?
| | Taxoids | 1 | 2004 | 116 | 0.050 |
Why?
| | Epigenesis, Genetic | 1 | 2009 | 669 | 0.050 |
Why?
| | Mesothelioma | 1 | 2004 | 50 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1505 | 0.050 |
Why?
| | Prognosis | 4 | 2016 | 4312 | 0.050 |
Why?
| | Osteosarcoma | 1 | 2004 | 76 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2004 | 176 | 0.050 |
Why?
| | Tissue Array Analysis | 2 | 2013 | 49 | 0.050 |
Why?
| | Sarcoma, Synovial | 1 | 2002 | 20 | 0.050 |
Why?
| | Fibroma, Desmoplastic | 1 | 2002 | 2 | 0.050 |
Why?
| | Ribs | 1 | 2002 | 35 | 0.050 |
Why?
| | Artifacts | 1 | 2003 | 142 | 0.050 |
Why?
| | Fibroblasts | 1 | 2007 | 1019 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2008 | 2117 | 0.040 |
Why?
| | Treatment Outcome | 4 | 2017 | 11734 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 779 | 0.040 |
Why?
| | Leukopenia | 2 | 2014 | 33 | 0.040 |
Why?
| | Fowlpox virus | 1 | 2019 | 1 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2011 | 2201 | 0.040 |
Why?
| | Administration, Intravesical | 1 | 2019 | 17 | 0.040 |
Why?
| | Pancreatic Neoplasms | 1 | 2008 | 926 | 0.040 |
Why?
| | Paraffin Embedding | 2 | 2010 | 31 | 0.040 |
Why?
| | Follow-Up Studies | 3 | 2017 | 5414 | 0.040 |
Why?
| | Phosphorylation | 2 | 2013 | 1704 | 0.040 |
Why?
| | Incidence | 2 | 2017 | 2892 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2006 | 1569 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 973 | 0.030 |
Why?
| | Practice Patterns, Physicians' | 1 | 2006 | 1360 | 0.030 |
Why?
| | International Agencies | 1 | 2016 | 30 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2004 | 1766 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 427 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2016 | 76 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2019 | 464 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2019 | 1363 | 0.030 |
Why?
| | Chemotherapy-Induced Febrile Neutropenia | 1 | 2014 | 2 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2010 | 1995 | 0.030 |
Why?
| | Early Termination of Clinical Trials | 1 | 2014 | 18 | 0.030 |
Why?
| | Myxoma | 1 | 2013 | 11 | 0.030 |
Why?
| | Adolescent | 4 | 2006 | 22405 | 0.020 |
Why?
| | Carcinoma, Small Cell | 1 | 2014 | 172 | 0.020 |
Why?
| | Histocytochemistry | 1 | 2013 | 78 | 0.020 |
Why?
| | Alopecia | 1 | 2013 | 37 | 0.020 |
Why?
| | Patient Selection | 1 | 2017 | 727 | 0.020 |
Why?
| | Genes, p53 | 1 | 2013 | 67 | 0.020 |
Why?
| | Chemoprevention | 1 | 2013 | 91 | 0.020 |
Why?
| | Cohort Studies | 2 | 2014 | 5957 | 0.020 |
Why?
| | Tamoxifen | 1 | 2013 | 191 | 0.020 |
Why?
| | Demography | 1 | 2013 | 287 | 0.020 |
Why?
| | Postoperative Period | 1 | 2013 | 351 | 0.020 |
Why?
| | Constipation | 1 | 2013 | 98 | 0.020 |
Why?
| | Microscopy | 1 | 2013 | 148 | 0.020 |
Why?
| | Estrogen Receptor alpha | 1 | 2013 | 151 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 392 | 0.020 |
Why?
| | Longevity | 1 | 2013 | 175 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2013 | 881 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2014 | 572 | 0.020 |
Why?
| | Fatigue | 1 | 2013 | 363 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 967 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 1742 | 0.020 |
Why?
| | Cetuximab | 1 | 2011 | 111 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 691 | 0.020 |
Why?
| | Pulmonary Gas Exchange | 1 | 2010 | 116 | 0.020 |
Why?
| | Estradiol | 1 | 2013 | 507 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2942 | 0.020 |
Why?
| | Respiratory Mechanics | 1 | 2010 | 73 | 0.020 |
Why?
| | Chromosome Aberrations | 1 | 2010 | 164 | 0.020 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2009 | 53 | 0.020 |
Why?
| | Karyotyping | 1 | 2009 | 105 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 2016 | 923 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2011 | 407 | 0.020 |
Why?
| | Homeostasis | 1 | 2013 | 639 | 0.020 |
Why?
| | Neoplasms, Adipose Tissue | 1 | 2009 | 1 | 0.020 |
Why?
| | Child | 2 | 2006 | 22599 | 0.020 |
Why?
| | Retinoblastoma Protein | 1 | 2009 | 61 | 0.020 |
Why?
| | Pilot Projects | 1 | 2014 | 1886 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2013 | 2033 | 0.020 |
Why?
| | Cell Movement | 1 | 2013 | 959 | 0.020 |
Why?
| | Connective Tissue Cells | 1 | 2007 | 2 | 0.020 |
Why?
| | Fixatives | 1 | 2007 | 13 | 0.020 |
Why?
| | Carbon Dioxide | 1 | 2010 | 239 | 0.020 |
Why?
| | Animals | 3 | 2019 | 37948 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2010 | 541 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2007 | 178 | 0.020 |
Why?
| | Formaldehyde | 1 | 2007 | 64 | 0.020 |
Why?
| | Stromal Cells | 1 | 2007 | 120 | 0.020 |
Why?
| | Swine | 1 | 2010 | 828 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2010 | 630 | 0.020 |
Why?
| | Thymus Gland | 1 | 2007 | 311 | 0.020 |
Why?
| | Mitochondria | 1 | 2013 | 984 | 0.020 |
Why?
| | Young Adult | 2 | 2013 | 14119 | 0.020 |
Why?
| | Specimen Handling | 1 | 2008 | 187 | 0.010 |
Why?
| | Anesthesia | 1 | 2010 | 258 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2922 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2013 | 2489 | 0.010 |
Why?
| | Coronary Vessels | 1 | 2007 | 246 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2009 | 441 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 835 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 3523 | 0.010 |
Why?
| | Preoperative Care | 1 | 2008 | 379 | 0.010 |
Why?
| | Itraconazole | 1 | 2004 | 7 | 0.010 |
Why?
| | Phenotype | 1 | 2013 | 3147 | 0.010 |
Why?
| | Metacarpus | 1 | 2004 | 6 | 0.010 |
Why?
| | Giant Cell Tumor of Bone | 1 | 2004 | 8 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 990 | 0.010 |
Why?
| | Hemodynamics | 1 | 2010 | 1113 | 0.010 |
Why?
| | Agranulocytosis | 1 | 2004 | 30 | 0.010 |
Why?
| | Oxygen | 1 | 2010 | 984 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2009 | 1246 | 0.010 |
Why?
| | Pneumonia | 1 | 2010 | 629 | 0.010 |
Why?
| | Antifungal Agents | 1 | 2004 | 150 | 0.010 |
Why?
| | Edema | 1 | 2004 | 124 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 2004 | 168 | 0.010 |
Why?
| | Retrospective Studies | 2 | 2014 | 17147 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2004 | 422 | 0.010 |
Why?
| | Secondary Prevention | 1 | 2004 | 255 | 0.010 |
Why?
| | Biomarkers | 1 | 2014 | 4261 | 0.010 |
Why?
| | Skin | 1 | 2007 | 762 | 0.010 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2002 | 47 | 0.010 |
Why?
| | Ki-67 Antigen | 1 | 2002 | 117 | 0.010 |
Why?
| | Radiography | 1 | 2004 | 848 | 0.010 |
Why?
| | Cytokines | 1 | 2010 | 2045 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2010 | 2815 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1079 | 0.010 |
Why?
| | Antigens, Neoplasm | 1 | 2002 | 272 | 0.010 |
Why?
| | Survival Rate | 1 | 2004 | 2089 | 0.010 |
Why?
| | Health Status | 1 | 2004 | 834 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5185 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2007 | 1788 | 0.010 |
Why?
| | Lung | 1 | 2010 | 4089 | 0.010 |
Why?
| | Mice | 1 | 2013 | 18261 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2002 | 1484 | 0.010 |
Why?
| | United States | 1 | 2004 | 16018 | 0.000 |
Why?
|
|
Aisner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|